Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

NCT03748186 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Ovarian Carcinoma
Ovary Cancer
Endometrial Cancer
Endometrioid Adenocarcinoma
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: STRO-002

Sponsor

Sutro Biopharma, Inc.